Cite
Clinical efficacy of enfortumab-pembrolizumab combination therapy in locally advanced/metastatic urothelial carcinoma (UC): A real-world experience.
MLA
Tripathi, Nikita, et al. “Clinical Efficacy of Enfortumab-Pembrolizumab Combination Therapy in Locally Advanced/Metastatic Urothelial Carcinoma (UC): A Real-World Experience.” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 643. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.4_suppl.643.
APA
Tripathi, N., Naqvi, S. A. A., Ballouz, T., Saxena, A., Bibi, A., Khan, M. A., Channar, A., Riaz, I. B., Tyson, M., Bryce, A. H., & Singh, P. (2024). Clinical efficacy of enfortumab-pembrolizumab combination therapy in locally advanced/metastatic urothelial carcinoma (UC): A real-world experience. Journal of Clinical Oncology, 42, 643. https://doi.org/10.1200/JCO.2024.42.4_suppl.643
Chicago
Tripathi, Nikita, Syed Arsalan Ahmed Naqvi, Tara Ballouz, Akshat Saxena, Arifa Bibi, Muhammad Ali Khan, Aneeta Channar, et al. 2024. “Clinical Efficacy of Enfortumab-Pembrolizumab Combination Therapy in Locally Advanced/Metastatic Urothelial Carcinoma (UC): A Real-World Experience.” Journal of Clinical Oncology 42 (February): 643. doi:10.1200/JCO.2024.42.4_suppl.643.